Speakers: Jason A. Salganick, MD & Larissa C., Patient Ambassador

Join us to learn more about ALK+ non-small cell lung cancer (NSCLC) and ALUNBRIG (brigatinib) as a treatment option for ALK+ NSCLC. Hear a healthcare professional speak about ALK+ NSCLC and ALUNBRIG (brigatinib). Hear the story and treatment experience of a person living with ALK+ NSCLC.

To register for this webinar, click here.

Acknowledgment: This event post is sponsored by Takeda and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing relevant, vetted and valuable information to the rare disease community.